2212a2a2a2a11 represents a cyclic nitroxide radical. In principle, the polymer micelle is parenterally administered to a patient or an organ donor prior to an organ exenteration in a surgery or transplant operation. In the case of a transplant operation, a removed organ is stored in a preservation solution containing the polymer micelle or is perfused with the preservation solution. Alternatively, in the case of a transplant operation, the polymer micelle is parenterally administered to a transplantation target patient. As a result, the ischemia-reperfusion-induced damage of an organ that is a target for the procedure of the operation is inhibited.
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention uses an image generation model to generate a second image in which the recognition accuracy of an object included in a first image is improved. An object included in the second image is subjected to recognition processing. Information obtained by the recognition processing of the object included in the second image is input to train the image generation model.
To improve the quality of sleep. A control device includes a determiner that determines a stage of sleep of a subject on the basis of biological information on the subject, and a controller that controls a sleep induction device including a beat generator that generates a binaural beat. The controller causes the beat generator to generate a binaural beat having a frequency lower than 1.0 Hz at least in the stage of sleep of the subject.
A61M 21/02 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscienceDispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p. ex. pour mettre en état d'hypnose pour provoquer le sommeil ou la relaxation, p. ex. par stimulation directe des nerfs, par hypnose ou par analgésie
A61M 21/00 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscienceDispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p. ex. pour mettre en état d'hypnose
4.
HYDROPHILIC-HYDROPHOBIC COPOLYMERS CARRYING DICHLOROACETIC ACID ON SIDE CHAIN AND MEDICAL USE THEREOF
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
Inventeur(s)
Nagasaki, Yukio
Yasui, Hironobu
Yamada, Sato
Inanami, Osamu
Abrégé
122 includes a dichloroacetyl group.) These copolymers or polymeric micelles which are formed from these copolymers in an aqueous medium have a tumor-specific radiation enhancement effect and enhance the therapeutic effect of radiation therapy on tumors. Consequently, the present invention provides a medical use of these copolymers or polymeric micelles for exerting such an effect.
An image processing device illuminates light from a light source through an optical system with a first numerical aperture onto an examined eye, transmits signal light returning from the examined eye through an optical system with a second numerical aperture, and divides a reference light from the light from the light source. The image processing device detects interference light between the signal light and the reference light, and acquires information representing the obtained interference light. The image processing device performs a first process of projecting the information representing the interference light onto a four-dimensional frequency aperture formed by the optical system with the first numerical aperture and the optical system with the second numerical aperture, in a four-dimensional space of frequencies of the light source and frequencies of light from the examined eye according to the signal light, and a second process of projecting the projected information into three-dimensional space.
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
The objective of the present invention is to provide a pendulum device in which the amplitude dependency of a restoring force of a pendulum due to gravity can be adjusted to a desired characteristic. To this end, a pendulum device (1) comprises a pendulum member (2) which is subjected to a restoring force due to gravity, performs a pendular movement around a shaft (32) serving as a fulcrum, and includes pendulum-side magnetic members (22a, 22b), and fixed magnetic members (4a, 4b) which impart a magnetic repulsive force or attractive force to the pendulum member (2) as a magnetic restoring force, wherein the pendulum device (1) is configured to provide a magnetic restoring force that cancels out a non-linear component of the restoring force due to gravity that acts on the pendulum member (2), by adjusting at least one of the magnetic flux density of at least one of the pendulum-side magnetic members (22a, 22b) and the fixed magnetic members (4a, 4b), the relative positions of the pendulum-side magnetic members (22a, 22b) and the fixed magnetic members (4a, 4b), and the mass of the pendulum member (2).
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
An underwater positioning system for accurate underwater positioning. At least one among at least one acoustic transmitter and at least one hydrophone is provided at known coordinates and which positions an unknown point having unknown coordinates at which another acoustic transmitter or hydrophone is provided, includes a time window that stores in advance, when the unknown point is set in a plurality of regions set by dividing an underwater positioning range, a time window for a sound wave emitted from the acoustic transmitter to reach the hydrophone for each of the regions, and a coordinate estimation and specification unit that calculates for each of the regions a time window-applied impulse response as an inner product of the time window and an impulse response of a sound wave propagation path from the acoustic transmitter to the hydrophone and estimates that the unknown point is located in the region where the energy of the time window-applied impulse response is maximized.
A concealment device includes at least one memory configured to store instructions and at least one processor configured to execute the instructions to generate a second string in which a substring of a first string detected as a concealment target has been replaced with another substring, and input the second string to a device that outputs a response to the second string.
An electrode 10 includes, as a catalyst, an alloy including three or more base metal elements, in which the three or more base metal elements are nearly equal in atomic composition proportion, and form a solid solution. Also, an electrode 12 includes: a carbon fiber; and a catalyst including a base metal, at least a part of elements of the catalyst being chemically bonded to the carbon fiber. Further, the water electrolyzer includes an anode, a cathode, and a solid polymer electrolyte membrane provided between the anode and the cathode. The anode is the electrode 10, and/or the cathode is the electrode 12.
C25B 13/08 - DiaphragmesÉléments d'espacement caractérisés par le matériau à base de matériaux organiques
H01M 4/90 - Emploi de matériau catalytique spécifié
10.
COPOLYMER CONTAINING POLY(ETHYLENE GLYCOL) SEGMENT AND REPEATING UNIT HAVING N-ACYLETHANOLAMINE OR HOMOLOGUE OR ANALOG THEREOF IN SIDE CHAIN, NANOPARTICLES OF SAID COPOLYMER, AND USE THEREOF
1-1212322CH(RO)NHC(=O)RL, C(=O)RL22222mm, m, A, and LMD are as described in formula (BC), x+y is an integer of 5-1400, z is an integer of 5-1400, x+y:z is 1:1-5, and x:y is 1:1-300).
C08F 20/36 - Esters contenant de l'azote contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C08G 81/02 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés au moins un des polymères étant obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone
11.
HYDROGEN STORAGE MATERIAL AND HYDROGEN DISCHARGING AND STORING SYSTEM
This hydrogen storage material includes: a borohydride-nickel carrier composed of borohydride and nickel supported on the borohydride; and magnesium hydride further supported on the borohydride-nickel carrier, wherein the content of the nickel is 5 mass% or less.
C01B 3/00 - HydrogèneMélanges gazeux contenant de l'hydrogèneSéparation de l'hydrogène à partir de mélanges en contenantPurification de l'hydrogène
C01B 35/18 - Composés contenant au moins trois atomes de bore, p. ex. NaB3H8, MgB10Br10
12.
TREATMENT AGENT FOR CANCER CACHEXIA OR SARCOPENIA, CONTAINING NANOPARTICLES DERIVED FROM POLYMERIZED CYCLIC NITROXIDE RADICAL COMPOUND AS ACTIVE INGREDIENT
Disclosed in the present invention is a cancer cachexia prophylactic or therapeutic agent which is a formulation containing, as an active ingredient, nano-sized particles consisting essentially of a graft polymer, or a base-added salt thereof, in which a residue of a cyclic nitroxide radical compound, a residue of a trialkoxyalkylsilane, and a poly(ethylene glycol) chain are inserted into a side chain of a poly(styrene-maleic anhydride) copolymer constituting the basic skeleton. When orally ingested, the prophylactic or therapeutic agent remains in the gastrointestinal tract for a long period of time with virtually no transfer into the blood and can reduce the symptoms of cancer cachexia or sarcopenia. Thus, the present disclosure provides a pharmaceutical formulation capable of effectively preventing or treating cancer cachexia or sarcopenia.
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/421 - 1,3-Oxazoles, p. ex. pémoline, triméthadione
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
13.
METHOD FOR QUANTIFYING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, METHOD FOR SCREENING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, THERAPEUTIC COMPOSITION, AND KIT
The present invention provides a technology useful for predicting prognosis in a follicular lymphoma patient. The present invention is a method for quantifying neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject, in order to determine the prognosis of follicular lymphoma. The method comprises: a flow cytometry step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with flow cytometry using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD-1 antibody, an anti-CD25 antibody, and an anti-TIM-3 antibody; or a multiplex immunostaining step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with multiplex immunostaining using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD -1 antibody, an anti-FOXP3 antibody, an anti-TCF-1 antibody, and an anti-Granzyme K antibody.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
14.
BIOELECTRODE, BIOELECTRODE PRODUCTION METHOD, ELECTROCHEMICAL DEVICE, BLOOD SUGAR LEVEL MEASUREMENT DEVICE, AND CONCENTRATION MEASUREMENT METHOD
A bioelectrode comprising: a complex compound composed of a metal and a ligand; a mediator having an anionic functional group; and an electroconductive material.
An assistance device that can independently control an assistance of a bending and stretching motion of a knee and an assistance of an upper body posture is provided. An assistance device includes a base, a first link fixed to the base, a second link rotatably coupled to the first link, a third link rotatably coupled to the second link, and an elastic connection portion incorporated between a predetermined position on the first link or the base and the third link.
A medical imaging device according to the present invention includes an illumination unit 11 that spot-illuminates a center of operative field of a surgical patient, an operative field camera unit 12 that images a center of irradiation range by the illumination unit 11, a housing 13 that covers the illumination unit 11 and the operative field camera unit 12, and a pair of display units 14 and 14 that are visible from both sides of the surgical patient.
One aspect of the present invention is a humanized anti-DNAM-1 antibody or an antigen-binding fragment thereof, including: a heavy chain variable region containing an amino acid sequence of SEQ ID NO: 1 as HCDR1, an amino acid sequence of SEQ ID NO: 2 as HCDR2, and an amino acid sequence of SEQ ID NO: 3 as HCDR3; and a light chain variable region containing an amino acid sequence of SEQ ID NO: 4 as LCDR1, an amino acid sequence of SEQ ID NO: 5 as LCDR2, and an amino acid sequence of SEQ ID NO: 6 as LCDR3.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
One aspect of the present invention is a humanized anti-DNAM-1 antibody or an antigen-binding fragment thereof, including: a heavy chain variable region containing an amino acid sequence of SEQ ID NO: 1 as HCDR1, an amino acid sequence of SEQ ID NO: 2 as HCDR2, and an amino acid sequence of SEQ ID NO: 3 as HCDR3; and a light chain variable region containing an amino acid sequence of SEQ ID NO: 4 as LCDR1, an amino acid sequence of SEQ ID NO: 5 as LCDR2, and an amino acid sequence of SEQ ID NO: 6 as LCDR3.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
19.
CULTURE MEDIUM FOR HUMAN CELLS, AND METHOD FOR CULTURING HUMAN HEMATOPOIETIC STEM CELLS
The present invention provides: a culture medium for culturing hematopoietic stem cells in vitro, the culture medium making it possible to selectively culture hematopoietic stem cells when a cell population containing the hematopoietic stem cells and cancer cells is cultured; and a method for culturing hematopoietic stem cells using the culture medium. The present invention relates to: a culture medium for human cells, the culture medium being intended to be used for culturing a cell population containing human cells, and the culture medium comprising a polyalkylene glycol modified by a copolymer of a polyvinylcaprolactam block and a polyvinyl acetate block, a phosphatidylinositol-3 kinase (PI3K) activator, a TPO receptor agonist, and one or more components selected from the group consisting of a proteasome inhibitor, a TNF-related apoptosis-inducing ligand and a cereblon modulator; and a method for culturing human hematopoietic stem cells, the method comprising culturing a cell population containing human hematopoietic stem cells in the aforementioned culture medium for human cells.
According to the present invention, a storage unit stores a depression risk evaluation model for calculating an evaluation value indicating the risk of depression by using a feature amount calculated from a prescribed frequency component obtained by decomposing brain waves by means of time-frequency analysis and having a value that changes in accordance with a change in the frequency of occurrence of a phase reset phenomenon. A feature amount calculation unit calculates the same type of feature amount as the feature amount used in the depression risk evaluation model from a prescribed frequency component obtained by decomposing the measured brain waves of a person-to-be-evaluated by means of time-frequency analysis. An evaluation unit calculates an evaluation value indicating the risk of depression of the person-to-be-evaluated by using the feature amount, which has been calculated by the feature amount calculation unit, as the input to the depression risk evaluation model.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
21.
GENOME-EDITED PLANT PRODUCTION METHOD AND GENOME-EDITED PLANT
Provided are: a genome-edited plant production method by which genome editing can be applied to plants including the family Leguminosae that is difficult to transform, without undergoing processes of tissue culture requiring transformation and time; and a genome-edited plant obtained by said method. The present invention pertains to a genome-edited plant production method and a genome-edited plant obtained by said method, the genome-edited plant production method comprising: providing a cutout in a part of a plant capable of autonomously growing; injecting, to the cutout, an Agrobacterium-containing solution for genome editing; introducing a mutation into the plant without leaving a foreign gene therein; and collecting seeds from the plant, into which the mutation has been introduced, without subjecting the plant to a re-differentiation step, to obtain a genome-edited plant.
A01H 1/00 - Procédés de modification des génotypes
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
A01H 6/54 - Leguminosae ou Fabaceae, p. ex. soja, luzerne ou arachide
Kanagawa Institute of Industrial Science and Technology (Japon)
University of Tsukuba (Japon)
Metagen, Inc. (Japon)
Inventeur(s)
Fukuda, Shinji
Nakato, Gaku
Obana, Nozomu
Furukawa, Risako
Abrégé
Determination of the mechanism of allergy development in which a bacterium of the family Lachnospiraceae, which is an enteric bacterium, including Ruminococcus gnavus is involved and developing a method for preventing or treating allergies by intervening in the mechanism. Since the Ibp protein from a bacterium of the family Lachnospiraceae is involved in development of allergies, allergic reactions occurring in vivo can be prevented by administration or induction of in vivo production of a substance that binds to the Ibp protein.
The present description discloses: a (ω-terminal modified) poly(ethylene glycol)-b-poly([R, S]-β-hydroxybutyrate) (PEG-b-PBHB) copolymer; nano-sized polymeric micelles or nanoparticles, which are formed from the copolymer and are capable of controlled release or sustained release of a low molecular weight β-hydroxybutyric acid in vivo; and production or preparation methods of these products, and a pharmaceutical use of the nanoparticles. Since the nanoparticles are capable of controlled release or sustained release of β-hydroxybutyric acid in vivo, physiological activity originally possessed by β-hydroxybutyric acid can be exhibited in vivo.
C08G 63/664 - Polyesters contenant de l'oxygène sous forme de groupes éther dérivés d'acides hydroxycarboxyliques
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C08J 3/09 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans des liquides organiques
The present invention comprises: a brain wave processing unit that acquires the amplitude and phase, for each of a prescribed plurality of frequency bands, from training brain wave data measured from one mammal living body, and executes a complexity analysis process comprising entropy analysis for each of the acquired amplitudes and phases of the frequency bands; and a machine learning unit that uses the result of the complexity analysis process and label data of a sleep/wakefulness stage corresponding to the training brain wave data so as to execute a machine learning process of a machine learning model for determining the sleep/wakefulness stage.
A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
TAIYO SERVICE INC. (Japon)
Inventeur(s)
Iwata, Yasushi
Matsui, Hirofumi
Suzuki, Iwane
Suzuki, Yuji
Tomita, Kanako
Yang, Tianjing
Ikeda, Takafumi
Kurokawa, Hiromi
Abrégé
Provided is an anticancer agent containing a substance that contains nitrogen-15 and that specifically accumulates in a cancer cell. Also provided is a method for killing a cancer cell in vitro, including accumulating nitrogen-15 in a cancer cell in vitro and irradiating the cancer cell with a proton beam in vitro. Additionally provided is a cancer treatment method including causing an accumulation of the nitrogen-15 in a cancer cell in a human or a nonhuman animal and irradiating the human or the nonhuman animal with a proton beam.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A therapeutic device estimates an outer shape of a target using an identifier that performed learning based on a first image capturing in vivo information of a subject, a second image showing the target in vivo, and a third image capturing the same subject using a different device from that used to capture the first image. In a configuration in which the shape of a target object site is learned using a DRR image processed from a CT image, the therapeutic device can accurately estimate the shape of the target object site.
An information processing device includes a reception unit that receives a plurality of OCT images captured under different image-capturing conditions and represented by complex signals, an image processing unit that performs digital refocusing by complex signal processing or digital aberration correction by the complex signal processing on each of the plurality of OCT images received by the reception unit, and a synthesis unit that synthesizes the plurality of OCT images on which the image processing unit has performed the digital refocusing by the complex signal processing or the digital aberration correction by the complex signal processing.
An intraocular illumination device includes a fiber that guides light from a light source, and a holder that is disposed between an objective lens of a microscope and an eye during eye surgery or examination and supports a tip portion of the fiber. The tip portion of the fiber is provided with a reflecting portion that reflects the light guided through the fiber toward an inside of the eye.
Provided is a gas supply device for short-time respiration that does not require skill and can make parasympathetic nerves dominant in a short time in order to suppress chronic stress without causing mood inhibition. A gas supply device 1 for short-time respiration comprises: a normal-pressure low-oxygen gas supply device 11 capable of supplying a normal-pressure gas having a predetermined oxygen concentration that does not cause mood inhibition when inhaled by a user for breathing; an oxygen saturation level detection device 32 capable of detecting an oxygen saturation level in the user; and a control device 20 which determines whether or not the oxygen saturation level in the user detected by the oxygen saturation level detection device 32 is equal to or greater than a predetermined value, and which, if it is determined that the oxygen saturation level in the user is less than the predetermined value, performs control to stop the normal-pressure low-oxygen gas supply device from producing and outputting the normal-pressure gas having the predetermined oxygen concentration to a gas output unit.
A61M 16/10 - Préparation de gaz ou vapeurs à respirer
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A63B 26/00 - Appareils d'exercice non couverts par les groupes
31.
ELECTRON SPIN RESONANCE DEVICE AND DETERIORATION EVALUATION METHOD
An electron spin resonance device includes a microwave oscillator, a magnet, a modulation coil, and a cavity resonator having an opening. A microwave generated in the microwave oscillator resonates in the cavity resonator and is emitted from the opening toward a measurement target located outside the opening. The magnet applies a magnetic field toward an irradiation surface of the measurement target, the irradiation surface being irradiated with the microwave. The modulation coil modulates an intensity of the magnetic field or a frequency of the microwave applied toward the irradiation surface of the measurement target irradiated with the microwave.
G01R 33/60 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance paramagnétique électronique
G01N 24/10 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance paramagnétique électronique
G01R 33/36 - Détails électriques, p. ex. adaptations ou couplage de la bobine au récepteur
32.
SEMICONDUCTOR APPARATUS AND METHOD FOR MANUFACTURING SEMICONDUCTOR APPARATUS
This semiconductor apparatus has a base film and a semiconductor film formed on the base film, wherein the base film comprises a polyimide obtained by condensation polymerization of an aromatic diamine and an aromatic tetracarboxylic acid anhydride and has a tensile elasticity in the machine direction of 7 GPa or more, and the semiconductor film is polycrystalline and comprises crystal particles having an average particle size of 1 μm or more.
As a method for manufacturing a carbon nanotube assembled wire, that is capable of manufacturing the carbon nanotube assembled wire in a tubular carbon nanotube synthesis furnace efficiently, an adhesion suppressing gas stream is generated from an adhesion suppressing gas discharge port located between a second end of the carbon nanotube synthesis furnace and an end of a heater closer to the second end, the adhesion suppressing gas stream flowing between an internal wall of the carbon nanotube synthesis furnace and an external wall of a first channel, in which carbon nanotubes are oriented to form the carbon nanotube assembled wire, in a direction from the second end toward a first end to suppress adhesion of a plurality of carbon nanotubes to the internal wall of the carbon nanotube synthesis furnace.
B01J 8/18 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés les particules étant fluidisées
C01B 32/162 - Préparation caractérisée par les catalyseurs
D01F 9/127 - Filaments de carboneAppareils spécialement adaptés à leur fabrication par décomposition thermique de gaz ou vapeurs d'hydrocarbures
RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
G21F 1/10 - Substances organiquesDispersions dans des supports organiques
G21F 3/00 - Blindage caractérisé par sa forme physique, p. ex. granulés, ou forme du matériau
H05K 9/00 - Blindage d'appareils ou de composants contre les champs électriques ou magnétiques
35.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
G21F 1/10 - Substances organiquesDispersions dans des supports organiques
G21F 3/00 - Blindage caractérisé par sa forme physique, p. ex. granulés, ou forme du matériau
H05K 9/00 - Blindage d'appareils ou de composants contre les champs électriques ou magnétiques
36.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
This neutron radiation shielding material for blocking neutron radiation contains a boride, and the average particle size of said boride is 500 μm or less.
G21F 1/10 - Substances organiquesDispersions dans des supports organiques
G21F 3/00 - Blindage caractérisé par sa forme physique, p. ex. granulés, ou forme du matériau
H05K 9/00 - Blindage d'appareils ou de composants contre les champs électriques ou magnétiques
37.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
This neutron radiation shielding material for blocking neutron radiation includes a resin-containing layer and a borohydride-containing layer, wherein one of the resin-containing layer and the borohydride-containing layer is disposed on a side exposed to the radiation source of neutron radiation.
G21F 1/10 - Substances organiquesDispersions dans des supports organiques
G21F 3/00 - Blindage caractérisé par sa forme physique, p. ex. granulés, ou forme du matériau
H05K 9/00 - Blindage d'appareils ou de composants contre les champs électriques ou magnétiques
38.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
A neutron radiation shielding material for blocking neutron radiation, wherein the attenuation rate of neutron radiation of 0.5 eV is 1e-2 or less when the thickness of the neutron radiation shielding material is 1 cm.
An information processing device according to an embodiment includes a learning unit that performs learning on a machine learning model having one or more non-polarization OCT images that are OCT images without polarization information as inputs and a pseudo polarization OCT image corresponding to a polarization OCT image that is an OCT image with polarization information as output; and a storage unit that stores a learning result of the learning unit.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G06T 5/60 - Amélioration ou restauration d'image utilisant l’apprentissage automatique, p. ex. les réseaux neuronaux
A method for manufacturing a carbon nanotube assembled wire includes: a first step of supplying a carbon-containing gas at one, first end of a tubular carbon nanotube synthesis furnace to grow a carbon nanotube from each of a plurality of catalyst particles suspended in the carbon nanotube synthesis furnace to synthesize a plurality of carbon nanotubes; a second step of orienting the plurality of carbon nanotubes in a longitudinal direction of the carbon nanotubes in a first channel provided in the carbon nanotube synthesis furnace, and thus assembling them together, to form a carbon nanotube assembled wire; and a third step of collecting the carbon nanotube assembled wire using a collecting gas stream flowing from a second end of the carbon nanotube synthesis furnace opposite to the first end in a direction away from the carbon nanotube synthesis furnace.
[Problem] To provide an antibody that binds with at least one of human CD300A-R and human CD300A-Q, does not bind with human CD300C, and inhibits binding between human CD300A and a ligand thereof. [Solution] Provided is an anti-human CD300A monoclonal antibody, or an antigen-binding fragment thereof, which satisfies requirement (i), (ii) or (iii) described in the description.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides an information processing device capable of setting meaningful upper and lower limits even in high-resolution data to perform sufficient verification. Provided is an information processing device (200) comprising: a smooth distance estimation means (203) that inputs an error rate and estimates a smoothed distance between a query image and a candidate image; and a rank range estimation means (204) that uses the smoothed distance to estimate a rank range. The information processing device inputs a different query image for the candidate image or a different candidate image for the query image. The information processing device comprises: a distance upper and lower limit estimation means (403) that estimates upper and lower limits of the distance between the query image and the candidate image; and a sufficient condition evaluation means (404) that evaluates whether the upper and lower limits of the distance are within the estimated rank range.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
43.
ORGANIC HYDRIDE PRODUCTION DEVICE AND ORGANIC HYDRIDE PRODUCTION METHOD
This organic hydride production device 2 comprises, as an anode catalyst 11, an anode electrode 10 having a high entropy alloy containing a base metal element, a cathode electrode 8, and an electrolyte membrane 12 positioned between the anode electrode 10 and the cathode electrode 8. The anode electrode 10 oxidizes water or hydroxide ions. The cathode electrode 8 electrochemically reduces a hydride to generate an organic hydride.
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stablesAssemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 11/052 - Électrodes comportant un substrat et un ou plusieurs revêtements électro-catalytiques
A MnBi-based magnet according to an embodiment includes crystal grains of (MnBi)aMb composition including a manganese element, a bismuth and a M element, wherein the M element is contained an amount of more than 0 at % and less than or equal to 10 at % when at % for all atoms of (MnBi)aMb is 100 at %, and the M element includes a chromium element, a germanium element, or a tellurium element.
Provided are a hydrogen boride-containing composition, a hydrogen generation system, and a fuel cell system that achieve further performance improvement of a hydrogen supply source with a hydrogen boride-containing sheet. The hydrogen boride-containing composition contains a hydrogen boride-containing sheet having a two-dimensional network consisting of (BH)n(n≥4, where n is an integer) and an electron donor. At least a portion of the electron donor is supported on the hydrogen boride-containing sheet, electrons of the electron donor are supplied to the hydrogen boride-containing sheet by external stimulus, and hydrogen is generated from the hydrogen boride-containing sheet into which the electrons are injected.
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C01B 6/00 - Hydrures de métauxMonoborane ou diboraneLeurs complexes d'addition
46.
METHOD FOR INTRODUCING SUBSTANCE INTO GENERATIVE CELLS
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Minagawa Sachi
Tanaka Saeko
Kurihara Mizuta Yoko
Wada Yusaku
Ezura Hiroshi
Kang Seung Won
Akase Kosuke
Worarad Kanjana
Mitalo Oscar Witere
Abrégé
This method for introducing a substance into generative cells comprises a step for combining a cell membrane-penetrating peptide containing an amphipathic amino acid sequence with the substance and introducing the resultant into pollen.
The present invention provides a plasma processing device capable of controlling the amount of water vapor added to an operating gas and the irradiation distance and widely controlling the wettability of the surface of a resin material that is the object. This plasma processing device performs plasma processing by irradiating an object (80) with atmospheric plasma (99). The plasma processing device comprises: a bubble generation container (64) for adding water vapor to an operating gas; a dew point meter (31) for adjusting the amount of water vapor added to the operating gas; a plasma generation unit (90) for generating atmospheric pressure plasma by applying high-frequency power to the operating gas in which the amount of water vapor added has been adjusted; a plasma delivery unit (91) for delivering the atmospheric pressure plasma toward the object; and an irradiation distance adjustment unit (400) for adjusting the plasma irradiation distance (L1) from the plasma delivery unit to the object.
A method for manufacturing a carbon nanotube assembled wire includes: a first step of supplying a carbon-containing gas to a plurality of catalyst particles in a suspended state in a tubular carbon nanotube synthesis furnace to grow a carbon nanotube from each of the plurality of catalyst particles to obtain a plurality of carbon nanotubes; and a second step of assembling the plurality of carbon nanotubes together to obtain a plurality of carbon nanotube assembled wires.
The purpose of this invention is to avoid accidental exposure of an infant patient in an infant incubator to a volatile substance. A purification device (2) is installed to an infant incubator (1) provided with a housing chamber (101), wherein the temperature and humidity inside the housing chamber (101) can be adjusted for housing an infant patient (X), and the purification device (2) purifies air including a volatile substance vaporized during medical practice with the volatile substance for an infant patient housed in the housing chamber (101). The purification device (2) comprises: a removal unit (3) for removing a volatile substance from air; a casing (4) capable of holding at least the removal unit (3); and a fixing unit (5) for fixing the casing (4) outside the infant incubator (1).
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
50.
INCUBATOR CONTROL DEVICE, INCUBATOR, VENTILATION DEVICE, AND INCUBATOR CONTROL METHOD
The present invention provides an incubator control device capable of adjusting, to appropriate ranges, the temperature and humidity in the interior of an accommodation chamber capable of accommodating an infant, said incubator control device being provided to an incubator. An incubator control device (200) is provided to an incubator (1) and comprises: a ventilation control unit (203) that controls at least one from among the amount of air supplied from the outside to the inside of an accommodation chamber (101) capable of accommodating an infant and the amount of air discharged from the inside to the outside of said accommodation chamber; and a temperature/humidity control unit (202) that controls the temperature and humidity in the interior of the accommodation chamber. The temperature/humidity control unit controls the ventilation control unit on the basis of information about the chamber interior temperature/humidity, which is the temperature and humidity in the interior of the accommodation chamber.
Provided is a valproic acid derivative for improving disadvantages or defects accompanying when valproic acid itself or the like is used as a medicine. Provided is a block copolymer which is a polymerized product of valproic acid and comprises a poly(ethylene glycol) segment and a poly(vinyl valproate) segment.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Kawanishi, Kunio
Kuno, Atsushi
Okatani, Chiaki
Sato, Takashi
Sakaue, Hiroaki
Kaji, Hiroyuki
Abrégé
Provided is a biomarker capable of specifically detecting renal cell cancer. Based on our finding that sialylation (sialic acid modification) is accentuated in the case of acquired cystic kidney disease associated renal cell carcinoma (ACD-RCC) compared to clear cell renal cell carcinoma (cc-RCC) from techniques in which cancer-specific regions are collected under a microscope from histopathology samples and diverse omics analyses such as lectin arrays and RNAseq, we have identified, by glycoproteomics that includes mass spectrometry, a glycoprotein group having a sugar chain structure containing a specific glycosylation, in particular, a sialylation, among protein groups from cancer tissue of renal cell cancer, and this glycoprotein group is provided as a new biomarker specific for renal cell cancer.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
53.
STRUCTURAL BODY INCLUDING BORON, HYDROGEN, AND OXYGEN, AND METHOD FOR PRODUCING SAME
The object of the present invention is to provide an excellent method for storing and transporting hydrogen.
The object of the present invention is to provide an excellent method for storing and transporting hydrogen.
The object can be solved by a structure comprising boron, hydrogen, and oxygen, that has B—H—B bonds, B—H bonds, and B—OH bonds, and in the measurement of FT-IR spectra, the following formulas are satisfied: (1) 0.80≤a/c≤0.96, and (2) 0.95≤b/c≤1.12, wherein when the baseline is defined as 100%, a is the transmittance at 1400 cm−1 in the FT-IR spectrum, b is the transmittance at 2500 cm−1 in the FT-IR spectrum, and c is the transmittance at 3200 cm−1 in the FT-IR spectrum.
This carbon nanotube assembly wire comprises a plurality of carbon nanotubes, wherein: the plurality of carbon nanotubes include a plurality of nitrogen-doped single-walled carbon nanotubes; the nitrogen content of the carbon nanotube assembly wire is 0.5 atom% to 6 atom% inclusive; and the content of graphitic nitrogen of the carbon nanotube assembly wire is 0.4 atom% to 3.5 atom% inclusive.
D01F 9/10 - Filaments, ou similaires, faits par l’homme, formés d’autres substancesLeur fabricationAppareils spécialement adaptés à la fabrication de filaments de carbone de matière inorganique par décomposition de substances organiques
According to the present invention, this depression level estimation device comprises a storage unit, a feature amount calculation unit, and an estimation unit. The storage unit stores a depression level estimation model. A depression level estimation model represents a correlation between a feature amount calculated from frequency components in a prescribed frequency range obtained by decomposing brainwaves of a measurement subject through time-frequency analysis and the depression level that represents the level of a depressed mood of the measurement subject. The feature amount calculation unit calculates the feature amount from the frequency components obtained by decomposing the measured brainwaves of the measurement subject through the time-frequency analysis. The estimation unit uses the depression level estimation model to estimate the depression level corresponding to the feature amount calculated by the feature amount calculation unit. As the feature amount, a variate, which varies according to the occurrence frequency of phase resetting, may be used.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A cold sensation presentation device includes: a cold stimulus section that contactlessly gives a cold stimulus to a skin; a warm stimulus section that contactlessly gives a warm stimulus to a skin; and a control unit that presents a cold sensation by causing a temporal change in the intensity of the cold stimulus in a cold stimulus state where the intensity of the warm stimulus is relatively small and a temporal change in the intensity of the warm stimulus in a warm stimulus state where the intensity of the warm stimulus is relatively large to be different from each other, and repeating the cold stimulus state and the warm stimulus state in a state of keeping the intensity of the cold stimulus constant.
Provided is a tissue-marking agent that improves the dispersion stability of fine particles labelled with a fluorescent dye in an aqueous medium. The present invention involves dispersing fine particles labelled with a fluorescent dye in an aqueous medium containing a water-soluble viscous substance.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
This conversion circuit converts an input current into an output voltage, and comprises: a first terminal that is an input section for the input voltage; a second terminal that is a ground; a third terminal that is an output section for the output voltage, and is for supplying a power source voltage via a power source supply resistor; a first resistor that is connected to the first terminal at one end and is connected to the third terminal and the other end; and a regulator that detects the difference between the voltage of the first terminal and a preset reference voltage, and when the voltage of the first terminal is higher than the reference voltage, performs control so as to adjust, in accordance with said difference, the quantity of current flowing from the third terminal to the second terminal, lower the voltage of the third terminal, and maintain the voltage of the first terminal at the reference voltage, wherein the gain of the conversion circuit is determined by the first resistor.
H03F 3/34 - Amplificateurs de courant continu dans lesquels tous les étages sont couplés en courant continu
G05F 1/613 - Régulation de la tension ou de l'intensité là où la variable effectivement régulée par le dispositif de réglage final est du type continu utilisant des dispositifs à semi-conducteurs en parallèle avec la charge comme dispositifs de réglage final
Provided is a gel material for ophthalmic treatment useful as a synthetic vitreous body which is a novel intraocular tamponade material having a low swelling pressure, an appropriate elastic force, and no toxicity to ocular tissues, specifically, to retinas, and which is capable of stably maintaining a long-term stable tamponade effect. A gel material for ophthalmic treatment including a hydrogel in which a gel precursor cluster crosslinks to form a three-dimensional network. The gel precursor cluster has a structure with crosslinked monomer units or crosslinked polymer units present at concentrations less than a critical gelation concentration, and the gel precursor cluster has a relationship of G′
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
This production device for a carbon nanotube wire comprises a first tube, a second tube, a first supply part, and a second supply part. The first tube has a first inner circumferential surface and an outer circumferential surface. The outer circumferential surface surrounds the first inner circumferential surface. The second tube has a second inner circumferential surface. The second inner circumferential surface surrounds the outer circumferential surface. The second inner circumferential surface extends along the outer circumferential surface. The first supply part supplies a raw material for carbon nanotubes and a chlorosulfonic acid into the first tube. The second supply part supplies a coagulant liquid into the second tube. The first tube has a first end. The first end lies inside the second tube.
This film formation method comprises step a) and step b). Step a) forms a metal oxide film. Step b) dopes the metal oxide film with a dopant, the dopant being such that, when the metal oxide film is doped therewith, an energy difference obtained by subtracting an energy by which the crystal structure of the metal oxide film becomes monoclinic from an energy by which the crystal structure becomes tetragonal is lower than an energy difference in the metal oxide film in an undoped state.
H01L 21/31 - Traitement des corps semi-conducteurs en utilisant des procédés ou des appareils non couverts par les groupes pour former des couches isolantes en surface, p. ex. pour masquer ou en utilisant des techniques photolithographiquesPost-traitement de ces couchesEmploi de matériaux spécifiés pour ces couches
H01L 21/425 - Bombardement par des radiations par des radiations d'énergie élevée produisant une implantation d'ions
62.
METHOD AND DEVICE FOR INDUCING HYPOMETABOLIC STATE IN SUBJECT WITH DISEASE
The present invention provides a method for inducing a hibernation-like state and an apparatus therefor. According to the present invention, provided is a method for decreasing a theoretical setpoint temperature of body temperature and a feedback gain of heat generation in a subject or a method for inducing a hibernation-like state in a subject, the method being a chemical and/or physical method including providing an excitatory stimulus to a pyroglutamylated RFamide peptide (QRFP)-producing neuron. According to the present invention, an apparatus used to practice this method is also provided.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/01 - Mesure de la température de parties du corps
A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p. ex. mesure du taux de consommation d'oxygène
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
63.
NUCLEIC ACID FOR GENE EXPRESSION USES, GENE EXPRESSION VECTOR, METHOD FOR PRODUCING GENE EXPRESSION VECTOR, AND GENE EXPRESSION METHOD
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species and cell species, can be predicted with respect to the expression amount thereof, and can be used in a gene expression vector having broad utility and capable of being used for an analysis at an organism individual level; and a gene expression vector, a method for producing the gene expression vector, and a gene expression method, in each of which the nucleic acid is used. Provided are: a nucleic acid for gene expression uses, which is intended to be use in a gene expression vector containing a recombinant enzyme expression gene, is introduced to the upstream of the recombinant enzyme expression gene, and comprises a sequence in which TA is repeated at least five times; and a gene expression vector, a method for producing the gene expression vector, and a gene expression method, in each of which the nucleic acid is used.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
65.
BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION
A body temperature lowering agent, a body temperature elevation suppressor, a food composition for lowering body temperature, and a food composition for suppressing body temperature elevation containing at least one substance selected from the group consisting of orotic acid, a derivative thereof, and a salt of the orotic acid or the derivative as an active ingredient.
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
66.
RADIATION SHIELDING JIG, METHOD FOR MANUFACTURING THE SAME, AND METHOD FOR USING THE SAME
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
The purpose of the present technology is to provide: a protein that has a protocatechuic acid 5-position oxidizing activity and can efficiently generate gallic acid from protocatechuic acid; and a microbial strain that expresses said protein. In the present invention, the use of a protocatechuic acid 5-position oxidizing enzyme derived from Comamonas microbes or a protein having at least 70% identity with the amino acid sequence of said protocatechuic acid 5-position oxidizing enzyme allows efficient production of gallic acid from protocatechuic acid. Gallic acid can be produced from protocatechuic acid as a result of fermentation using a microbial strain into which a gene that codes for said enzyme has been introduced.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nucleic acid construct including a polynucleotide that codes for at least two types of T cell epitopes and a polynucleotide that codes for one or more types of B cell epitopes for the target protein. The present invention makes it possible to powerfully induce antibodies against a target protein within the body of a subject, making it possible not only to induce antibody production against exogenous antigens such as bacteria and viruses but also to induce antibody production against proteins produced within the body of the self.
C12N 15/40 - Protéines de virus à ARN, p. ex. flavivirus
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
69.
PRODUCTION METHOD FOR MICROFIBRILLATED CELLULOSE MOLDED ARTICLE, AND MICROFIBRILLATED CELLULOSE MOLDED ARTICLE
This method is for producing a microfibrillated cellulose molded article formed of a microfibrillated cellulose and a phenolic resin. The method for producing a microfibrillated cellulose molded article comprises: a step for preparing a first preliminary molded sheet formed of a microfibrillated cellulose and 0-10 mass% of water; a step for obtaining a second preliminary molded sheet by exposing the first preliminary molded sheet to water for at least one hour to swell the sheet; a step for obtaining a third preliminary molded sheet by replacing the water contained in the second preliminary molded sheet with a solution containing a phenolic resin having a weight-average molecular weight of at most 1000; a step for drying the obtained third preliminary molded sheet; and a step for thermally pressing the dried third preliminary molded sheet by applying a pressure of 1-10 MPa to the sheet in the thickness direction at a temperature of 120-200°C.
D21H 19/24 - Couches sans pigments appliquées sous une forme autre que la solution aqueuse définie dans le groupe comprenant des composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
D21H 11/18 - Fibres hautement hydratées, gonflées ou aptes à être fibrillées
70.
APPARATUS USED TO DETECT OR STIMULATE ACTIVITY OF NERVE TISSUE
This apparatus (1) comprises at least one intravascular device (10), (20) that is disposed in a blood vessel of an organism and that is equipped with at least one electrode (11), (12), (21), (22) for detecting or stimulating the activity of nerve tissue positioned outside the blood vessel nearby, the electrodes (11), (12), (21), (22) being provided on a wire member.
A61B 5/293 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
71.
COMPOSITION CONTAINING BOROHYDRIDE SHEET AND CARRIER, AND HYDROGEN RELEASE METHOD USING SAME
The purpose of the present invention is to provide: a composition which is capable of efficiently releasing hydrogen; and a hydrogen release method. The above are achieved by means of a composition which contains a borohydride sheet and a carrier at a volume ratio of 1:0.1 to 100 so that the transmittance of ultraviolet light is more than 0% but less than 100%.
A secondary battery of the present disclosure includes a positive electrode, an electrolyte layer, a negative electrode current collector, and metallic lithium as a negative electrode active material that is deposited between the electrolyte layer and the negative electrode current collector by charging, an intermediate layer is present between the electrolyte layer and the negative electrode current collector, and the intermediate layer contains hydrogen boride.
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventing inflammation caused by Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, an antiprotozoal composition that contains a composite formed by joining lysozyme and chitosan, an anti-attachment agent for Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, and the like.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides a method for producing natural polymer microspheres, the method including: adding a solution containing a natural polymer (e.g., an aqueous fibroin solution) to an organic solvent, the organic solvent having a surfactant dissolved therein, and homogenizing the resulting mixed solution to generate a natural polymer colloidal suspension; and adding the natural polymer colloidal suspension to an alcohol having 3 or more carbon atoms to form natural polymer microspheres.
A contact lens-shaped intraocular lighting device comprising: a contact lens including a dome-shaped first region that is provided in a central portion and through which light is transmitted, a ring-shaped second region that extends outward in a radial direction from an outer peripheral portion of the first region, and a ring-shaped third region that extends outward in the radial direction from an outer peripheral portion of the second region and is provided to be in contact with the sclera; and a lighting unit that is provided in the second region of the contact lens, adjusts refraction or diffusion of light provided from a light source, and emits the light into the eye.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Nosato, Hirokazu
Kochi, Yuta
Sakanashi, Hidenori
Murakawa, Masahiro
Ikeda, Atsushi
Abrégé
An endoscopic diagnosis support method whereby an examined area and an unexamined area can be clearly discriminated. After a preparatory step of an observation canvas is performed in advance, a frame marking step, a key point calculation step, a preceding and following frame displacement amount calculation step, a preceding and following frame marking step are executed to thereby perform observation recording. In an image diagnosis support step IDS, support is performed such that the existence of a lesion is diagnosed in an organ on the basis of a plurality of position data marked with respect to a plurality of frames in the observation canvas data and an endoscopic image in the plural frames.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p. ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
77.
ORGAN DEFORMATION ESTIMATION DEVICE, TREATMENT DEVICE, TREATMENT ASSISTANCE DEVICE, ORGAN DEFORMATION ESTIMATION METHOD, AND PROGRAM
This organ deformation estimation device is provided with: a three-dimensional model acquisition unit which acquires a three-dimensional model that shows the shape of an organ, the three-dimensional model being generated on the basis of a three-dimensional image of the organ which has been captured previously before the implementation of a treatment; a captured image acquisition unit which acquires a captured image that is an image of the inside of the organ which has been captured during the process of the treatment; a partial image extraction unit which extracts a partial image from the three-dimensional image; an alignment unit which performs the alignment of the captured image with the partial image; a target position calculation unit which calculates a target position on the basis of the result of the alignment; and a displacement estimation unit which estimates the deformation of the organ during the process of the treatment by deforming the three-dimensional model on the basis of a three-dimensional simulation in such a manner that the position of a part corresponding to the inside among parts constituting the three-dimensional model is displaced to the target position.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
78.
Non-transitory computer readable recording medium, information processing method and information processing apparatus
A non-transitory computer-readable recording medium has stored therein a program that causes a computer to execute a process, the process including acquiring movie data including a plurality of consecutive frames calculating first likelihood of a class of the movie data by inputting the acquired movie data to a trained model, calculating an optical flow indicating movement of an area included in the movie data, based on the movie data generating occluded movie data by setting an occluded area in each of the frames included in the movie data, based on the optical flow, calculating second likelihood of a class of the occluded movie data by inputting the occluded movie data to the model identifying an area that affects identification of the class among areas in the movie data, based on the first likelihood and the second likelihood and displaying the identified area that affects identification of the class.
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 20/40 - ScènesÉléments spécifiques à la scène dans le contenu vidéo
79.
INFORMATION PROCESSING METHOD, INFORMATION PROCESSING SYSTEM, AND COMPUTER PROGRAM
The present invention provides an information processing method, an information processing system, and a computer program. According to the present invention, a computer executes processing that: acquires respective first intermediate representations from a plurality of devices, the first intermediate representations being obtained by applying an intermediate representation conversion function to first data used individually at the devices; acquires respective second intermediate representations from the plurality of devices, the second intermediate representations being obtained by applying the intermediate representation conversion function to second data used in common at the devices; adjusts a parameter for an integrated representation conversion function to minimize the difference in integrated representations obtained by applying the integrated representation conversion function to each of the respective second intermediate representations acquired from the devices; and, on the basis of each of the respective first intermediate representations acquired from the devices and the integrated representation conversion function after adjustment of the parameter, derives a device difference correction function for correcting the device difference between the plurality of devices.
An objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor, which has high bioavailability, low toxicity, and high therapeutic effectiveness, even when provided by oral administration. Another objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor which is effective in preventing or treating hepatic disorders. In order to achieve the above objectives, an acyl group is introduced into the primary amino group in the side chain of an ornithine unit in the poly(ornithine) segment of poly(ethylene glycol)-b-poly(ornithine), which spontaneously forms polymer micelles without polyion complex formation.
To stably support a user before and after posture transition between a standing position and a sitting position by suppressing forward and backward movement of a position of the center of gravity of a user without power supply with a simple configuration. A stable support mechanism includes a base, a support structure mounted on the base, the support structure being configured to be capable of translational movement along a first axis in a plane horizontal to the base, the support structure being configured to be capable of changing a posture between a first position and a second position in a plane perpendicular to the base, and a link having a fixed length, one end of the link being connected to the base, the other end of the link being connected to the support structure, the link being configured to guide the support structure in a direction along the first axis along with changing the posture of the support structure.
Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
83.
FEATURE AMOUNT SELECTION DEVICE, FEATURE AMOUNT SELECTION METHOD, AND PROGRAM
A feature amount selection device includes a feature amount data acquisition unit that acquires feature amount data including a set of values of a plurality of feature amounts for a sample, for each of a plurality of the samples, a principal component analysis unit that performs, on the feature amount data, principal component analysis in a sample space that is a collection of the plurality of feature amounts of a set of values for each of the plurality of the samples of the feature amounts, and a feature amount selection unit that selects a feature amount from among the plurality of the feature amounts based on a result of the principal component analysis performed by the principal component analysis unit.
A method for reconstructing an interior CT image in which a region of interest in an object is irradiated with X-rays and an image of the region of interest in a cross section of the object is reconstructed, wherein the method includes: a projection data acquisition step in which a plurality of pieces of projection data are acquired for an occasion on which the region of interest of the object is irradiated with X-rays in a predetermined angular range in the circumferential direction of the object; and an image calculation step in which when matrices holding pixel information for an occasion on which X-rays pass through a cross section of the object in accordance with the irradiation angle serve as projection calculation matrices, a vector in which the plurality of pieces of projection data are arranged is denoted by b, a matrix in which a plurality of the projection calculation matrices corresponding to the projection data are arranged is denoted by A, and a vector in which the image values of the cross section of the object are arranged is denoted by x, Ax = b is solved under prior information C and an image of the region of interest is determined, said prior information C being the sum of the image values of an image of the cross section of the object.
A secure computation system comprising secure computation server apparatuses, each of which comprises: a discriminant share generation part that computes discriminant shares configured so that an index relating to an input corresponds to a specific value from shares representing the index relating to the input and possible combinations of index shares of an array; a combination configuration part that configures a combination of shares of an element in the array and the discriminant shares for all possible combinations of indices of the array; a shuffle part that shuffles the combinations; a reconstruction part that reconstructs the discriminant shares in the shuffled combinations; and a selection part that selects shares of an element in the array in the combinations where the reconstructed value is the specific value.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
An image display device displays a stereoscopic image by using a parallax barrier method and includes a transmissive image display surface on which images of left-eye image data and right-eye image data are alternately displayed; an image forming unit including optical members having strip-shaped patterns with optical properties arranged on a surface located on a back surface side of the image display surface; and strip-shaped light sources arranged on an illumination arrangement surface, which is a surface located on a back surface side of the image forming unit, and configured to irradiate the image display surface with illumination light. A slit area of the parallax barrier method is formed by an image obtained by forming an image of the illumination light from the strip-shaped light sources on the back surface side of the image display surface by using the optical members of the image forming unit.
H04N 13/312 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c.-à-d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe étant situées derrière l’affichage, p. ex. entre la source de rétroéclairage et le modulateur spatial de lumière [MSL]
H04N 13/305 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c.-à-d. utilisant des affichages autostéréoscopiques utilisant des lentilles lenticulaires, p. ex. dispositions de lentilles cylindriques
H04N 13/315 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c.-à-d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe variant dans le temps
87.
GENE INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR PRODUCING MUSCLE TISSUE AND METHOD FOR PRODUCING EDIBLE MEAT
Provided are: a gene inducing differentiation into fast muscle fibers, said gene being capable of increasing or suppressing the ratio of fast muscle fibers in a muscle tissue and preventing or restoring muscle weakness caused by, for example, aging, injuries or diseases, etc.; a composition for inducing differentiation into fast muscle fibers; a method for inducing differentiation into fast muscle fibers; a method for producing a muscle tissue; and a method for producing an edible meat. A gene inducing differentiation into fast muscle fibers, said gene including a gene encoding a fast muscle fiber differentiation inducing factor comprising any of proteins MafA, MafB and c-Maf; and a composition for inducing differentiation into fast muscle fibers, a method for inducing differentiation into fast muscle fibers, a composition for inhibiting differentiation into fast muscle fibers, a method for inhibiting differentiation into fast muscle fibers, a method for producing a muscle tissue and a method for producing an edible meat, each mainly using the aforesaid gene.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
The purpose of the present invention is to provide a volatile material monitoring system that can accurately acquire the concentration of a volatile material, e.g., ethanol, in an incubator and thereby enable suitable management of the influence exercised by the volatile material on the health of a pediatric patient. The volatile material monitoring system comprises: one or a plurality of sensors (14a, 14b, 14c) disposed in an incubator (1) comprising a housing compartment (101) having a temperature- and humidity-regulatable interior in order to house a pediatric patient (X), wherein the sensor or sensors detect the concentration of a volatile material used due to medical intervention on a pediatric patient (X) in the housing compartment (101); and an estimation unit (161) that estimates, on the basis of the volatile matter concentration detected by the sensors (14a, 14b, 14c), the volatile matter blood concentration in the blood of the pediatric patient (X).
The present invention removes volatile substances from air in an incubator. A purification device (120) includes: an air intake part (121b) for taking in air; a suction part (125) for sucking the air; a second removal part (126) for removing volatile substances, which are substances used in medical intervention on an infant patient, from the air sucked by the suction part (125); and an exhaust part (122b) for exhausting the air from which the volatile substances have been removed by the second removal part (126).
The purpose of the present invention is to avoid the accidental exposure of an infant patient in an infant incubator to a volatile substance. This infant incubator (3) is provided with: a housing chamber (101) in which an infant patient (X) can be housed; and a removal section (134) for removing a volatile substance from air in the housing chamber (101).
F24F 7/003 - Ventilation combinée avec le nettoyage de l'air
F24F 8/158 - Traitement, p. ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p. ex. par filtrage par des moyens chimiques utilisant du charbon actif
91.
VOLATILE SUBSTANCE REMOVAL APPARATUS AND VOLATILE SUBSTANCE REMOVAL METHOD
Provided is a volatile substance removal apparatus capable of sufficiently removing volatile substances such as ethanol floating around a child patient in an incubator. The volatile substance removal apparatus (110, 210, 110A) comprises: a suction unit (115) for suctioning air inside a storage chamber (101) from an intake unit (111c); a removal unit (114, 116) for removing volatile substances contained in the air; an exhaust unit (111d) for exhausting the air from which the volatile substances have been removed by the removal unit (114, 116); and a guide unit (112, 212) for guiding air to the intake unit (111c).
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Solution] Neural cells are cultivated in the presence of feeder cells including at least one type of cells selected from the group consisting of vascular component cells, perivascular cells, and oligodendrocytes.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
An imaging lighting instrument for an operation is disposed in a space between an operator's head and a patient, thereby configuring a multi-viewpoint video capturing device for a surgical operation in which blocking of a light by the operator's head or body and appearance of the head in a video are avoided. The imaging lighting instrument includes a plurality of cameras and a plurality of lights attached to a hollow ring-shaped or arc-shaped housing made of a wire member of a finite length, which is devised so as not to interfere with the visual field or work of the operator. Furthermore, the multi-viewpoint video capturing device is configured to have a function of estimating the context of the plurality of cameras and make it possible to perform operation support/recording of a direct-view surgical operation by using a multi-viewpoint video by adding a video information processing function for selecting a camera video in which an operators' hand or surgical instruments less appear in an image.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A rocking device includes: a seat which supports a body of a user; a motor which rotates a rotation shaft in a first rotation direction and in a second rotation direction that is a rotation direction opposite to the first rotation direction, and thereby supplies motive power for rocking the seat via a gear attached to the rotation shaft; and a controller which controls rocking of the seat via the motor. The seat is configured to make a first motion of moving in a first movement direction, in accordance with rotation of the rotation shaft in the first rotation direction, and make a second motion of moving in a second movement direction, in accordance with rotation of the rotation shaft in the second rotation direction. The controller is configured to control rocking of the seat such that a prescribed stopped period is provided between the first motion and second motion.
An information processing apparatus acquires an image; generates a shielding image in which a part of an area included in an area of the acquired image has been shielded; calculates, by inputting the image to a first model that has been trained, first likelihood of the target object included in the image; calculates, by inputting the shielding image to a second model that calculates an approximation value of likelihood of the target object included in the image when the image is input, second likelihood corresponding to the approximation value of the likelihood of the target object included in the shielding image; specifies, based on the first likelihood and the second likelihood, an area that affects discrimination of the class and that is included in the area of the image; and displays the specified area that affects discrimination of the class.
G06V 10/36 - Utilisation d’un opérateur local, c.-à-d. des moyens pour opérer sur des points d’image situés dans la proximité d’un point donnéOpérations de filtrage locales non linéaires, p. ex. filtrage médian
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Higashi Taishi
Motoyama Keiichi
Onodera Risako
Matsumoto Yoshitaka
Abrégé
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclodextrin molecules, a single straight-chain molecule passing through the openings in the plurality of cyclodextrin molecules in a skewer-like manner, and a blocking group which is provided at both ends of the single straight-chain molecule and prevents the cyclodextrin molecules and the straight-chain molecule from separating, wherein at least some of the cyclodextrin molecules bind, via a linker, to boronic acid or a monovalent group derived therefrom.
This image processing device emits light from a light source onto an examined eye through an optical system of a first numerical aperture, and acquires information indicating interference light obtained by detecting interference light between signal light, in which light returning from the examined eye owing to the light emitted thereon is transmitted through an optical system of a second numerical aperture, and reference light, which is a division of light from the light source (S200). A first process (S202) is performed for projecting information indicating the interference light to a four-dimensional frequency aperture that is on a four-dimensional space of the light source frequency and the frequency of light from the examined eye owing to the signal light, and is formed by the optical system of the first numerical aperture and the optical system of the second numerical aperture. A second process (S204) is performed for projecting the projected information to a three-dimensional space.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
99.
METHOD FOR TREATING PATIENT HAVING UNDERGONE PRE-TRANSPLANTATION PROCESS INVOLVED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND COMPOSITION FOR USE IN SAID METHOD
The present disclosure provides: a method for treating a patient who has undergone a pre-transplantation process involved in hematopoietic stem cell transplantation; and a composition for use in said method. The composition according to the present disclosure contains bone-marrow common progenitor cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
A stage of sleep is easily estimated. A sleep estimation device includes a first acquisition unit configured to acquire blood flow data, a generation unit configured to generate a frequency spectrum of the blood flow data by performing frequency analysis processing on the blood flow data, and a first determination unit configured to determine a stage of sleep of a subject based on the frequency spectrum.
brevets
